---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-011401"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:54:52.476546+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Zomedica Q2 2022 revenue $4.2M, up 51% pro-forma; net loss $5.3M, cash $186.8M

## Summary
- Revenue $4.2M (71% gross margin), up 51% pro-forma vs combined $2.8M in Q2 2021.
- PulseVet revenue $4.2M (+48% standalone); small animal systems sold 22 (20x increase).
- Net loss $5.3M ($0.005/sh) vs $4.7M loss in Q2 2021; 6-month loss $9.2M ($0.009/sh).
- Cash $186.8M; used $5.5M in quarter including $1M convertible note in SMP (VetGuardian).
- Post-quarter acquisitions: Revo 2 imaging assets and Assisi LOOP/Calmer Canine products.

## SEC filing metadata
- accession: 0001654954-22-011401
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495422011401/0001654954-22-011401-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495422011401/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-011401
- JSON: https://secwatch.observer/filing/0001654954-22-011401.json
- Plain text: https://secwatch.observer/filing/0001654954-22-011401.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.